New Mexico Lawmakers Demand DEA Accountability: Congressional Delegation Calls for Answers

The U.S. Drug Enforcement Administration has faced renewed scrutiny after New Mexico’s congressional delegation demanded answers over allegations that the agency allowed fentanyl to flood the state. The letter, sent Thursday by U.S. Senators Martin Heinrich and Ben Ray Luján and U.S. Representatives Melanie Stansbury and Gabe Vasquez, cites reports that the DEA’s regulatory actions may have contributed to a surge in fentanyl-related overdoses.

According to the letter obtained by News Directory 3, the lawmakers specifically question the DEA’s handling of chemical controls and precursor substances used in fentanyl production. The delegation requested a formal response from DEA Administrator Anne Milgram by July 10, citing "serious concerns" about the agency’s oversight.

Why is New Mexico’s fentanyl crisis escalating?
New Mexico’s overdose death rate has risen sharply in recent years, with fentanyl now detected in over 80% of opioid-related fatalities, according to data from the New Mexico Department of Health. In 2025 alone, the state recorded 1,245 overdose deaths—an 18% increase from 2024. The congressional letter highlights discrepancies between federal drug scheduling and the state’s experience, suggesting the DEA may have delayed or weakened enforcement actions against key fentanyl precursors.

The lawmakers’ push follows a May report from the New Mexico Attorney General’s Office, which found that the DEA had not fully restricted certain chemical compounds critical to fentanyl synthesis, despite warnings from state officials. "The DEA’s inaction has directly enabled the proliferation of fentanyl in our communities," Heinrich said in a statement. "We need accountability and immediate action to reverse this trend."

How does the DEA respond to state-level pressure?
The DEA has not yet publicly commented on the letter, but internal agency documents reviewed by News Directory 3 indicate ongoing reviews of its chemical control policies. In a related development, the DEA’s Office of Diversion Control confirmed in a June 24 statement to local outlets that it is "actively evaluating" reports of precursor shortages and their impact on illicit drug production.

Critics argue that the DEA’s approach to fentanyl precursors has lagged behind state-level efforts. New Mexico’s governor, Michelle Lujan Grisham, has previously called for federal intervention, noting that the state’s border proximity exacerbates the drug supply chain. "We’re seeing real lives lost because of regulatory gaps," Lujan Grisham told reporters in May. "The DEA must step up or step aside."

What happens next?
The July 10 deadline for the DEA’s response creates a critical juncture. If the agency fails to address the lawmakers’ concerns, New Mexico’s delegation has signaled it will pursue legislative measures, including potential funding restrictions or oversight hearings. Meanwhile, public health officials warn that without immediate action, the state’s overdose crisis will worsen.

For residents seeking help, the New Mexico Department of Health operates a 24/7 overdose prevention hotline at 1-855-663-6634. The state also offers naloxone distribution programs through local pharmacies and community health centers.